Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets

Clynes, Raphael A., Towers, Terri L., Presta, Leonard G., Ravetch, Jeffrey V.·2000·Nature Medicine

DOI 10.1038/74704

Cited by (1,006)

Items 801–900 of 1,006

Effects of HER Family–targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer
Denis Martin Collins, Stephen F. Madden, Nicola Gaynor, Dalal AlSultan, Marion Le Gal, Alex J. Eustace, Kathy A. Gately, Clare Hughes, Anthony Mitchell Davies, Thamir Mahgoub et al. · 2020 · Clinical Cancer Research
Epidermal growth factor receptor‐targeted treatment for advanced colorectal carcinoma
Alan Paul Venook · 2005 · Cancer
Down-regulation of Polo-like Kinase 1 Elevates Drug Sensitivity of Breast Cancer CellsIn vitroandIn vivo
Birgit Spänkuch, Sandra Heim, Elisabeth Kurunci‐Csacsko, Christine Lindenau, Juping Yuan, Manfred Kaufmann, Klaus Strebhardt · 2006 · Cancer Research
Novel Insights into Anti-CD40/CD154 Immunotherapy in Transplant Tolerance
David F. Pinelli, Mandy L. Ford · 2015 · Immunotherapy
Therapeutic approaches for HER2-positive brain metastases: Circumventing the blood–brain barrier
Ankit Indravadan Mehta, Adam Brufsky, John Howard Sampson · 2012 · Cancer Treatment Reviews
Therapeutic Efficacy of Astatine-211–Labeled Trastuzumab on Radioresistant SKOV-3 Tumors in Nude Mice
Stig Palm, Tom A. Bäck, Ingela Claesson, Anna Danielsson, Jörgen Elgqvist, Sofia H.L. Frost, Ragnar Hultborn, Holger J. Jensen, Sture Lindegren, Lars Jacobsson · 2007 · International Journal of Radiation Oncology*Biology*Physics
Combination Immunotherapy of B-Cell Non-Hodgkin’s Lymphoma with Rituximab and Interleukin-2
Charles F. Eisenbeis, Andrew Grainger, Beth Fischer, Robert A. Baiocchi, Lester Carrodeguas, Sameek Roychowdhury, Lei Chen, Amy L. Banks, Thomas A. Davis, Donn C. Young et al. · 2004 · Clinical Cancer Research
Treatment With Autologous Antigen-Presenting Cells Activated With the HER-2 –Based Antigen Lapuleucel-T: Results of a Phase I Study in Immunologic and Clinical Activity in HER-2–Overexpressing Breast Cancer
John W. Park, Michelle Melisko, Laura J. Esserman, Lori A. Jones, Jami Breen Wollan, Robert Brownell Sims · 2007 · Journal of Clinical Oncology
Structure and Cancer Immunotherapy of the B7 Family Member B7x
Hyungjun Jeon, Vladimir I. Vigdorovich, Sarah C. Garrett-Thomson, Murali Janakiram, Udupi Anantharamachar Ramagopal, Yael M. Abadi, Jun Sik Lee, Lisa Scandiuzzi, Kim C. Ohaegbulam, Jordan M. Chinai et al. · 2014 · Cell Reports
The ErbB2ΔEx16 splice variant is a major oncogenic driver in breast cancer that promotes a pro-metastatic tumor microenvironment
Jason Turpin, C Ling, Erika J. Crosby, Zachary C. Hartman, Alexandra M. Simond, Lewis A. Chodosh, Jonathan P. Rennhack, Eran R. Andrechek, John Ozcelik, Michael T. Hallett et al. · 2016 · Oncogene
HER2-positive breast cancer is lost in translation: time for patient-centered research
Isabelle Gingras, Géraldine Gebhart, Evandro de Azambuja, Martine J Piccart · 2017 · Nature Reviews Clinical Oncology
Targeting Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor 2 (HER2) Expressing Bladder Cancer Using Combination Photoimmunotherapy (PIT)
Mohammad R. Siddiqui, Reema S. Railkar, Thomas H. Sanford, Daniel R. Crooks, Michael Eckhaus, Diana C. Haines, Peter L. Choyke, Hisataka Kobayashi, Piyush Kumar Agarwal · 2019 · Scientific Reports
Asymmetrical Fc Engineering Greatly Enhances Antibody-dependent Cellular Cytotoxicity (ADCC) Effector Function and Stability of the Modified Antibodies
Zhi Liu, Kannan Gunasekaran, Wei Wang, Vladimir I. Razinkov, Laura Sekirov, Esther C. Leng, Heather Sweet, Ian N. Foltz, Monique Howard, Anne-Marie Rousseau et al. · 2013 · Journal of Biological Chemistry
Sustained benefit in rheumatoid arthritis following one course of rituximab: improvements in physical function over 2 years
Vibeke Strand, Alexandra Balbir‐Gurman, Karel Pavelká, Paul Emery, N. Li, Margaret Har Yin, Patricia B. Lehane, S. Agarwal · 2006 · Lara D. Veeken
Neratinib, A Novel HER2-Targeted Tyrosine Kinase Inhibitor
Shruti Rakesh Tiwari, Prasun J. Mishra, Jame Abraham · 2016 · Clinical Breast Cancer
breast cancer cells
Naciba Benlimame, MA Alaoui-Jamali, Mortimer B. Davis · 2009
HER2 in Breast Cancer Stemness: A Negative Feedback Loop towards Trastuzumab Resistance
Babak Nami, Zhixiang Wang · 2017 · Cancers
Neonatal Fc receptor expression in macrophages is indispensable for IgG homeostasis
Dilip K. Challa, Xiaoli Wang, Héctor Pérez Montoyo, Ramraj Velmurugan, Raimund J. Ober, Elizabeth Sally Ward · 2019 · mAbs
Resistance to Trastuzumab
Sneha Vivekanandhan, Keith L. Knutson · 2022 · Cancers
Novel asymmetrically engineered antibody Fc variant with superior FcγR binding affinity and specificity compared with afucosylated Fc variant
Futa Mimoto, Tomoyuki Igawa, Taichi Kuramochi, Hitoshi Katada, Shojiro Kadono, Takayuki Kamikawa, Meiri Shida-Kawazoe, Kunihiro Hattori · 2013 · mAbs
Differential binding to human FcγRIIa and FcγRIIb receptors by human IgG wildtype and mutant antibodies
Kathryn L. Armour, Jan G. J. van de Winkel, Lorna M. Williamson, Mike Clark · 2003 · Molecular Immunology
Building better magic bullets — improving unconjugated monoclonal antibody therapy for cancer
Louis M. Weiner · 2007 · Nature reviews. Cancer
A Case of Metastatic Extramammary Paget’s Disease Responding to Trastuzumab plus Paclitaxel Combination Therapy
Fumie Hanawa, Takashi Inozume, Kazutoshi Harada, Tatsuyosi Kawamura, Naotaka Shibagaki, Shinji Shimada · 2011 · Case Reports in Dermatology
Recombinant Anti-CD20 Antibody Fragments for Small-Animal PET Imaging of B-Cell Lymphomas
Tove Olafsen, David J. Betting, Vania E. Kenanova, Felix B. Salazar, P J Clarke, JONATHAN W. SAID, Andrew Antony Raubitschek, John M. Timmerman, Anna M. Wu · 2009 · Journal of Nuclear Medicine
The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burden
Péter Boross, J.H. Marco Jansen, Simone de Haij, Frank J M Beurskens, Cees E. van der Poel, Lisette Bevaart, Maaike Nederend, Josée Golay, Jan G. J. van de Winkel, Paul W.H.I. Parren et al. · 2011 · Haematologica
Immunobiology of the sentinel lymph node and its potential role for antitumour immunity
Ryungsa Kim, Manabu Emi, Kazuaki Tanabe, Koji Arihiro · 2006 · The Lancet Oncology
Mac-1 (CD11b/CD18) is crucial for effective Fc receptor–mediated immunity to melanoma
Annemiek B. van Spriel, Heidi H. van Ojik, Annie Bakker, Marco Jansen, Jan G. J. van de Winkel · 2002 · Blood
Overcoming Resistance to HER2-Directed Therapies in Breast Cancer
Ilana Miriam Schlam, Paolo Tarantino, Sara M. Tolaney · 2022 · Cancers
Murine Models of B-Cell Lymphomas: Promising Tools for Designing Cancer Therapies
Sabrina Donnou, Claire Galand, Valérie Touitou, Catherine Sautès‐Fridman, Zsuzsanna Fábry, Sylvain Fisson · 2012 · Advances in Hematology
The ErbB2 Signaling Network as a Target for Breast Cancer Therapy
Ali Badache, Anthony Gonçalvès · 2006 · Journal of Mammary Gland Biology and Neoplasia
Afucosylated Antibodies Increase Activation of FcγRIIIa-Dependent Signaling Components to Intensify Processes Promoting ADCC
Scot D. Liu, Cecile M. Chalouni, Judy C. Young, Teemu T. Junttila, Mark X. Sliwkowski, John B. Lowe · 2014 · Cancer Immunology Research
Rituximab induces sustained reduction of pathogenic B cells in patients with peripheral nervous system autoimmunity
Michael Maurer, Goran Rakočević, Carol Sze Ki Leung, Isaak Quast, Martin Lukačišin, Norbert Goebels, Christian Münz, Hedda Wardemann, Marinos C. Dalakas, Jan D. Lünemann · 2012 · Journal of Clinical Investigation
Role of IgE receptors in IgE antibody-dependent cytotoxicity and phagocytosis of ovarian tumor cells by human monocytic cells
Sophia N. Karagiannis, Marguerite G. Bracher, Rebecca L. Beavil, Andrew J. Beavil, James Hunt, Natalie McCloskey, Richard G. Thompson, Nicholas East, Frances Burke, Brian J. Sutton et al. · 2007 · Cancer Immunology Immunotherapy
A Chimeric Multi-Human Epidermal Growth Factor Receptor-2 B Cell Epitope Peptide Vaccine Mediates Superior Antitumor Responses
Naveen K. Dakappagari, John A. Pyles, Robin Parihar, William Edgar Carson, Donn C. Young, Pravin T. P. Kaumaya · 2003 · The Journal of Immunology
Targeting of RGD‐modified proteins to tumor vasculature: A pharmacokinetic and cellular distribution study
Astrid J. Schraa, Robbert J. Kok, Henk E. Moorlag, Erwin J. Bos, Johannes H. Proost, Dirk K. F. Meijer, Lou F. M. H. de Leij, Grietje Molema · 2002 · International Journal of Cancer
Modern Technologies for Creating Synthetic Antibodies for Clinical Application
Sergey Mikhailovich Deyev, Ekaterina N. Lebedenko · 2009 · Acta Naturae
Intratumoral Injection of α-gal Glycolipids Induces Xenograft-Like Destruction and Conversion of Lesions into Endogenous Vaccines
Uri Galili, Kim Wigglesworth, Ussama M. Abdel‐Motal · 2007 · The Journal of Immunology
Disruption of cell-cell adhesion enhances antibody-dependent cellular cytotoxicity: implications for antibody-based therapeutics of cancer.
Shane K. Green, Mikael C. I. Karlsson, Jeffrey V. Ravetch, Robert S. Kerbel · 2002 · PubMed
Understanding key assay parameters that affect measurements of trastuzumab-mediated ADCC against Her2 positive breast cancer cells
Timothy Kute, John Stehle, David A. Ornelles, Natalie K. Walker, Osvaldo Delbono, James P. Vaughn · 2012 · OncoImmunology
ErbB-directed immunotherapy: Antibodies in current practice and promising new agents
Elza Friedländer, Márk Barok, János Szöllõsi, György Vereb · 2008 · Immunology Letters
Promoting tolerance to proteolipid protein-induced experimental autoimmune encephalomyelitis through targeting dendritic cells
Joel N. H. Stern, Derin B. Keskin, Zenichiro Kato, Hanspeter Waldner, Sonja Schallenberg, Ana Carrizosa Anderson, Harald von Boehmer, Karsten Kretschmer, Jack L. Strominger · 2010 · Proceedings of the National Academy of Sciences
A Human ICAM-1 Antibody Isolated by a Function-First Approach Has Potent Macrophage-Dependent Antimyeloma Activity In Vivo
Niina Veitonmäki, Markus Hansson, Fenghuang Zhan, Annika Sundberg, Tobias Löfstedt, Anne Ljungars, Zhanchun Li, Titti Martinsson Niskanen, Ming Zeng, Ye Yang et al. · 2013 · Cancer Cell
Identification of Clinically Significant Tumor Antigens by Selecting Phage Antibody Library on Tumor Cells in Situ Using Laser Capture Microdissection
Weiming Ruan, Adam A. Sassoon, Feng An, Jeff P. Simko, Bin Liu · 2006 · Molecular & Cellular Proteomics
In Pancreatic Carcinoma, Dual EGFR/HER2 Targeting with Cetuximab/Trastuzumab Is More Effective than Treatment with Trastuzumab/Erlotinib or Lapatinib Alone: Implication of Receptors' Down-regulation and Dimers' Disruption
Christel Larbouret, Nadège Gaborit, Thierry Chardès, Mickaël Coelho, Emmanuelle Campigna, Caroline Mollévi, Jean‐Pierre Mach, D. Azria, Bruno Robert, André Pèlegrin · 2012 · Neoplasia
B cell depletion therapy in systemic lupus erythematosus
Jennifer H. Anolik, Iñaki Sanz, Richard John Looney · 2003 · Current Rheumatology Reports
Investigating the Combination of Trastuzumab and HER2/neu Peptide Vaccines for the Treatment of Breast Cancer
Elizabeth Ann Mittendorf, Catherine E. Storrer, Craig D. Shriver, Sathibalan Ponniah, George Earl Peoples · 2006 · Annals of Surgical Oncology
Cetuximab therapy in head and neck cancer: Immune modulation with interleukin-12 and other natural killer cell–activating cytokines
Luedke, Eric, Jaime-Ramirez, Alena Cristina, Bhave, Neela, Roda, Julie, Choudhary, Moaz Maqbool, Kumar, Bhavna, Teknos, Theodoros N., Carson, William E. · 2012 · Surgery
Circulating myeloid-derived suppressor cells increase in patients undergoing neo-adjuvant chemotherapy for breast cancer
Wesolowski, Robert, Duggan, Megan C., Stiff, Andrew, Markowitz, Joseph, Trikha, Prashant, Levine, Kala M., Schoenfield, Lynn, Abdel-Rasoul, Mahmoud, Layman, Rachel, Ramaswamy, Bhuvaneswari et al. · 2017 · Cancer Immunology, Immunotherapy
Immunotherapy for prostate cancer: recent developments and future challenges
Michael Thomas Schweizer, Charles G. Drake · 2014 · Cancer and Metastasis Reviews
Antibody-Dependent Cellular Cytotoxicity (ADCC)
Raúl Gómez Román, Joseph Christopher Murray, Louis M. Weiner · 2013 · Elsevier eBooks
FCγ Chimeric Receptor-Engineered T Cells: Methodology, Advantages, Limitations, and Clinical Relevance
Sara Caratelli, Tommaso Sconocchia, Roberto Arriga, Andrea Coppola, Giulia Lanzilli, Davide Lauro, Adriano Venditti, Maria Ilaria Del Principe, Francesco Buccisano, Luca Maurillo et al. · 2017 · Frontiers in Immunology
B Cells in Patients With Melanoma: Implications for Treatment With Checkpoint Inhibitor Antibodies
Zena N. Willsmore, R. J. C. Harris, Silvia Crescioli, Khuluud Hussein, Helen Kakkassery, Deepika Thapa, Anthony Cheung, Jitesh Chauhan, Heather J. Bax, Alicia M. Chenoweth et al. · 2021 · Frontiers in Immunology
A combination of Trastuzumab and 17-AAG induces enhanced ubiquitinylation and lysosomal pathway-dependent ErbB2 degradation and cytotoxicity in ErbB2-overexpressing breast cancer cells
Srikumar M. Raja, Robert J. Clubb, Mitra Bhattacharyya, Manjari Dimri, Hao Cheng, Wei Pan, Cesar Francisco Ortega-Cava, Alagarsamy Lakku Reddi, Mayumi Naramura, Vimla Band et al. · 2008 · Cancer Biology & Therapy
Crystal Structure of HIV-1 Primary Receptor CD4 in Complex with a Potent Antiviral Antibody
Michael M. Freeman, Michael S. Seaman, Sophia Rits‐Volloch, Xinguo Hong, Chia-Ying Kao, David D. Ho, Bing Chen · 2010 · Structure
Genes Affecting the Cell Cycle, Growth, Maintenance, and Drug Sensitivity Are Preferentially Regulated by Anti-HER2 Antibody through Phosphatidylinositol 3-Kinase-AKT Signaling
Xiao‐Feng Le, Amy Lammayot, David Lee Gold, Yiling Lu, Weiqun Mao, Teresa Chang, Adarsh M. Patel, Gordon Brent Mills, Robert C. Bast · 2004 · Journal of Biological Chemistry
Generation of Rituximab Polymer May Cause Hyper-Cross-linking–Induced Apoptosis in Non-Hodgkin's Lymphomas
Nan Zhang, Leslie A. Khawli, Peisheng Hu, Alan L. Epstein · 2005 · Clinical Cancer Research
NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma
Esther Moga, Eva Álvarez, Elisabet Cantó, Sílvia Vidal, José Luis Rodríguez-Sánchez, Jorge Sierra, Javier Briones · 2007 · Experimental Hematology
Single-Domain Antibody–Based and Linker-Free Bispecific Antibodies Targeting FcγRIII Induce Potent Antitumor Activity without Recruiting Regulatory T Cells
Caroline Rozan, Amélie Cornillon, Corinne Pétiard, Martine Chartier, Ghislaine Béhar, Charlotte Boix, Brigitte Kerfélec, Bruno Robert, André Pèlegrin, Patrick Chames et al. · 2013 · Molecular Cancer Therapeutics
Polymorphonuclear Granulocytes Induce Antibody-Dependent Apoptosis in Human Breast Cancer Cells
Bernhard Stockmeyer, Thomas D. Beyer, Winfried Neuhuber, Roland Repp, Joachim R. Kalden, Thomas Valerius, Martin Herrmann i · 2003 · The Journal of Immunology
A full complement of receptors in immune complex diseases
Jeffrey V. Ravetch · 2002 · Journal of Clinical Investigation
Treating human autoimmune disease by depleting B cells
R. John Looney · 2002 · Annals of the Rheumatic Diseases
AACR Cancer Progress Report 2013
Charles L. Sawyers, Cory T. Abate-Shen, Kenneth Carl Anderson, Anna D. Barker, Jose M Baselga, Nathan A. Berger, Margaret Foti, Ahmedin Jemal, Theodore Steven Lawrence, Christopher I. Li et al. · 2013 · Clinical Cancer Research
Plant Virus Particles Carrying Tumour Antigen Activate TLR7 and Induce High Levels of Protective Antibody
Jantipa Jobsri, Alex Allen, Deepa Rajagopal, Michael J. Shipton, K. Kanyuka, George P. Lomonossoff, Christian H. H. Ottensmeier, Sandra S. Diebold, Freda K. Stevenson, Natalia Savelyeva · 2015 · PLoS ONE
Prognostic influence of tumor-infiltrating mast cells in patients with follicular lymphoma treated with rituximab and CHOP
Minna Taskinen, Marja‐Liisa Karjalainen‐Lindsberg, Sirpa Leppä · 2008 · Blood
huBC1-IL12, an immunocytokine which targets EDB-containing oncofetal fibronectin in tumors and tumor vasculature, shows potent anti-tumor activity in human tumor models
Kin-Ming Lo, Lan Yan, Scott Lauder, Jinyang Zhang, Beatrice A Brunkhorst, Guozhong Qin, Rakesh Verma, Nigel S. Courtenay-Luck, Stephen D. Gillies · 2006 · Cancer Immunology Immunotherapy
Rituximab as a Therapeutic Tool in Severe Mixed Cryoglobulinemia
Dario Roccatello, Simone Baldovino, Daniela Rossi, Osvaldo Giachino, Morteza Mansouri, Carla Naretto, Debora Di Simone, Simona Francica, Roberto Cavallo, Mirella Alpa et al. · 2007 · Clinical Reviews in Allergy & Immunology
Serum HER2 testing in patients with HER2-positive breast cancer: the death knell tolls
Brian R Leyland-Jones, Brian R Smith · 2011 · The Lancet Oncology
Correlation of HER2, FCGR2A, and FCGR3A gene polymorphisms with trastuzumab related cardiac toxicity and efficacy in a subgroup of patients from UNICANCER-PACS04 trial
Lise Roca, Veronique C Dieras, Henri Hubert Roche, Emmanuelle Lappartient, Pierre Kerbrat, Laurent Cany, Stéphanie Chièze, Jean-Luc Re Canon, M. Spielmann, Frederique Madeleine Penault-Llorca et al. · 2013 · Breast Cancer Research and Treatment
Breast tumor cells isolated from in vitro resistance to trastuzumab remain sensitive to trastuzumab anti-tumor effects in vivo and to ADCC killing
Timothy Edward Kute, Lori Savage, John Stehle, Jung Wha Kim-Shapiro, Michael J Blanks, James C. S. Wood, James P. Vaughn · 2009 · Cancer Immunology Immunotherapy
Lapatinib inhibits receptor phosphorylation and cell growth and enhances antibody‐dependent cellular cytotoxicity of EGFR‐ and HER2‐overexpressing esophageal cancer cell lines
Kousaku Mimura, Koji Kono, Takanori Maruyama, Mitsuaki Watanabe, Shinichirou Izawa, Shugo Shiba, Yoshiki Mizukami, Yoshihiko Kawaguchi, Masayuki Inoue, Tetsuo Kono et al. · 2011 · International Journal of Cancer
PTEN Loss Is Associated with Worse Outcome in HER2 -Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance
Howard Marvin Stern, Humphrey Gardner, Tomasz Burzykowski, Wafaa A. Elatre, Carol Lynn O'Brien, Mark R. Lackner, Gary Anthony Pestano, Angela Santiago, Ivonne E. Villalobos, Wolfgang EIERMANN et al. · 2015 · Clinical Cancer Research
Anti-epidermal growth factor receptor monoclonal antibody cetuximab inhibits EGFR/HER-2 heterodimerization and activation
Chunsheng Kang · 1992 · International Journal of Oncology
Beyond trastuzumab: New treatment options for HER2-positive breast cancer
Kamal S. Saini, Hatem A. Azim, Otto Metzger, Sherene Loi, Christos P. Sotiriou, Evandro de Azambuja, Martine J Piccart · 2011 · The Breast
CD95 in cancer: tool or target?
Ana Martín-Villalba, Enric Llorens-Bobadilla, Damian Wollny · 2013 · Trends in Molecular Medicine
Expression of the 5T4 oncofoetal antigen in renal cell carcinoma: a potential target for T-cell-based immunotherapy
R W Griffiths, David Edward Gilham, Adam Dangoor, Vijay Ramani, Noel William Clarke, Peter L. Stern, Robert E. Hawkins · 2005 · British Journal of Cancer
Stemming Resistance to HER-2 Targeted Therapy
Philippe Lucien Bedard, Fátima Cardoso, Martine J Piccart · 2009 · Journal of Mammary Gland Biology and Neoplasia
Recommendations on management of EGFR inhibitor-induced skin toxicity: A systematic review
Jara M. Baas, Lisanne L. Krens, Henk‐Jan Guchelaar, J. Ouwerkerk, Floris A. de Jong, Adriana P.M. Lavrijsen, Hans A. J. Gelderblom · 2011 · Cancer Treatment Reviews
DCIR2+ cDC2 DCs and Zbtb32 Restore CD4+ T-Cell Tolerance and Inhibit Diabetes
Jeffrey D. Price, Chie Hotta-Iwamura, Yongge Zhao, Nicole Marie Beauchamp, Kristin V. Tarbell · 2015 · Diabetes
Cross-Priming of Cytotoxic T Cells Promoted by Apoptosis-Inducing Tumor Cell Reactive Antibodies?
Nicole Selenko-Gebauer, Otto Majdic, Ulrich Jaeger, Christian Sillaber, Johannes Stöckl, Walter Knapp · 2002 · Journal of Clinical Immunology
Redundant and Alternative Roles for Activating Fc Receptors and Complement in an Antibody-Dependent Model of Autoimmune Vitiligo
Jiri Trcka, Yoichi Moroi, Raphael Clynes, Stacie M. Goldberg, Amy Bergtold, Miguel‐Angel Perales, Minghe Ma, Cristina Rosa Ferrone, Michael C. Carroll, Jeffrey V. Ravetch et al. · 2002 · Immunity
Boosting ADCC and CDC activity by Fc engineering and evaluation of antibody effector functions
Christian Kellner, Stefanie Derer, Thomas Valerius, Matthias Peipp · 2013 · Methods
Tumor immunotherapy: New aspects of natural killer cells
Yangxi Li, Rui Sun · 2018 · Chinese Journal of Cancer Research
Application of 212Pb for Targeted α-particle Therapy (TAT): Pre-clinical and Mechanistic Understanding through to Clinical Translation
Kwon Joong Yong, Martin W. Brechbiel · 2015 · AIMS Medical Science
Cross‐talk between pathogen recognizing Toll‐like receptors and immunoglobulin Fc receptors in immunity
Marjolein van Egmond, Gestur Vidarsson, Jantine E. Bakema · 2015 · Immunological Reviews
Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance
Daniele Cretella, Francesca Saccani, Federico Quaini, Caterina Frati, Costanza Annamaria Lagrasta, Mara A. Bonelli, Cristina Caffarra, Andrea Cavazzoni, Claudia Fumarola, Maricla Galetti et al. · 2014 · Molecular Cancer
Analysis of CD20-dependent cellular cytotoxicity by G-CSF-stimulated neutrophils
LE van der Kolk, Masja de Haas, A.J. Grillo-López, Johanna W. Baars, MHJ van Oers · 2002 · Leukemia
Phase I Immunotherapy Trial with Two Chimeric HER-2 B-Cell Peptide Vaccines Emulsified in Montanide ISA 720VG and Nor-MDP Adjuvant in Patients with Advanced Solid Tumors
Tanios Bekaii‐Saab, Robert Wesolowski, Daniel H. Ahn, Christina Sing-Ying Wu, Amir Mortazavi, Maryam B. Lustberg, Bhuvaneswari Ramaswamy, Jeffrey M. Fowler, Lai Wei, Jay P. Overholser et al. · 2019 · Clinical Cancer Research
Tumor targeting of the IL‐15 superagonist RLI by an anti‐GD2 antibody strongly enhances its antitumor potency
Marie Vincent, Anne Bessard, Denis Cochonneau, Géraldine Teppaz, Véronique Solé-Jamault, Mike Maillasson, Stéphane Birklé, Laure Garrigue‐Antar, Agnès Quéméner, Yannick Jacques · 2013 · International Journal of Cancer
Fcγ Receptor Dependency of Agonistic CD40 Antibody in Lymphoma Therapy Can Be Overcome through Antibody Multimerization
Ann L. White, Lang Dou, H.T. Claude Chan, Vikki L. Field, Christopher Ian Mockridge, Kane Moss, Emily L. Williams, Steven G. Booth, Ruth R. French, Elizabeth A. Potter et al. · 2014 · The Journal of Immunology
T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody
Mounia Sabrina Braza, Bernard Klein, Geneviève Fiol, Jean‐François Rossi · 2010 · Haematologica
Recent advances of novel targeted therapy in non-small cell lung cancer
Jed Abraham Katzel, Michael Paul Fanucchi, Zujun Li · 2009 · Journal of Hematology & Oncology
The small molecule TGF-β signaling inhibitor SM16 synergizes with agonistic OX40 antibody to suppress established mammary tumors and reduce spontaneous metastasis
Kendra Garrison, Tobias Hahn, Wen‐Cherng Lee, Leona E. Ling, Andrew D. Weinberg, Emmanuel T. Akporiaye · 2011 · Cancer Immunology Immunotherapy
Biologic and immunologic effects of preoperative trastuzumab for ductal carcinoma in situ of the breast
Henry M. Kuerer, Aman U. Buzdar, Elizabeth Ann Mittendorf, Francisco J. Esteva, Anthony Lucci, Luis M. Vence, Laszlo George Radvanyi, Funda Meric‐Bernstam, Kelly K. Hunt, W. Fraser Symmans · 2010 · Cancer
Impact of Intrinsic Affinity on Functional Binding and Biological Activity of EGFR Antibodies
Yu Zhou, Anne-Laure Goenaga, Brian D. Harms, Hao Zou, Jianlong Lou, Fraser Conrad, Gregory Paul Adams, Birgit Schoeberl, Ulrik B. Nielsen, James D. Marks · 2012 · Molecular Cancer Therapeutics
Defucosylated Anti–CC Chemokine Receptor 4 Monoclonal Antibody Combined with Immunomodulatory Cytokines: A Novel Immunotherapy for Aggressive/Refractory Mycosis Fungoides and Sezary Syndrome
Hiroki Yano, Takashi Ishida, Atsushi Inagaki, Toshihiko Ishii, Jianmin Ding, Shigeru Kusumoto, Hirokazu Komatsu, Shinsuke Iida, Hiroshi Inagaki, Ryuzo Ueda · 2007 · Clinical Cancer Research
Expression profiling of B cell chronic lymphocytic leukemia suggests deficient CD1-mediated immunity, polarized cytokine response, altered adhesion and increased intracellular protein transport and processing of leukemic cells
Z Zheng, Sumathi Venkatapathy, Geetha Rao, CA Harrington · 2002 · Leukemia
Effective anti-neu-initiated antitumor responses require the complex role of CD4+ T cells
Mortenson, Eric D., Park, SaeGwang, Jiang, Zhujun, Wang, Shengdian, Fu, Yang-Xin · 2013 · Clinical Cancer Research
Molecular determinants of trastuzumab efficacy: What is their clinical relevance?
Pradip K.R De, Max Hasmann, Brian R Leyland-Jones · 2013 · Cancer Treatment Reviews
Immunopathogenesis of lymphoma: Focus on CCR4
Takashi Ishida, Ryuzo Ueda · 2010 · Cancer Science
Targeting immune effector cells to promote antibody-induced cytotoxicity in cancer immunotherapy
Roch Houot, Holbrook E K Kohrt, Aurélien Marabelle, Ronald Levy · 2011 · Trends in Immunology